Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is proud to announce the launch of its D
The Nobel Prize in Physiology or Medicine awarded
This year, the Hamburg based life sciences company
Alembic Pharmaceuticals Ltd., t
Since it’s an ingredient in so many foods, you h
Dear Readers, Welcome to the latest issue of Micr
Sanofi’s assurance in its own coronavirus vaccine candidates has increased this summer as the French drugmaker prepares to commence clinical trials, its chief executive told Reuters.
The company is working on two of their more than 150 potential vaccines being developed throughout the world to tackle the COVID-19 pandemic, which has maintained over 831,000 lives and ignited economic chaos.
One offender, to be fabricated on the back of an present platform which develops vaccines to deal with influenza, will use an adjuvant created by Britain’s GlaxoSmithKline (GSK) to improve its effectiveness.
FILE PHOTO: Paul Hudson, Chief Executive Officer of Sanofi
The other, being developed using U.S. firm Translate Bio, is based on another technology known as mRNA.
“The first data is stating that we’re on the perfect path and that we now have a vaccine,” Paul Hudson said in an interview Friday, speaking to this vaccine being developed with GSK.
This vaccine is place to start clinical trials next month.
